Daily Biopharma Digest · May 22, 2026
CVC and GBL Launch €10.7 Billion Tender Offer for Recordati
Today’s Highlights
- Major M&A moves and clinical setbacks shape today’s biopharma agenda.
- CVC Capital Partners and GBL launched a €10.7 billion tender offer to take Italian pharma Recordati private.
- Gilead completed its acquisition of antibody-drug conjugate specialist Tubulis worth up to $5 billion.
- Biogen and Denali abandoned their LRRK2 inhibitor after Phase 2b failure in Parkinson’s.
- Eli Lilly released new analyses showing its oral GLP-1 Foundayo (orforglipron) achieved up to 13% weight loss in older adults.
- The EMA’s CHMP issued positive opinions, including AstraZeneca’s camizestrant in HR+ breast cancer and Boehringer Ingelheim’s nerandomilast in IPF.
What to Watch
- Recordati deal closure — Analyst skepticism around the €10.7 billion CVC-GBL tender offer suggests potential regulatory or shareholder obstacles that could derail the privatization attempt.
- Avidity platform expansion — Novartis’ efforts to apply Avidity’s RNA-targeting technology beyond muscular dystrophy will test whether the $12 billion acquisition can generate returns across multiple therapeutic areas.
- LRRK2 mechanism reassessment — The Biogen-Denali Phase 2b failure may prompt the field to reconsider LRRK2 inhibition strategies in sporadic Parkinson’s, though genetic subset opportunities may persist.
- Oral GLP-1 adoption curve — Lilly’s positive data in older adults positions Foundayo to potentially capture patient segments prioritizing convenience over injectable options, intensifying competition with Novo Nordisk.
